Andrys Ctirad

Publications (3)2.35 Total impact

• Article: Serum level of sCD30 molecule but not sCD30L in patients with psoriasis is reduced by Goeckerman's therapy.

  Andrys Ctirad, Krejsek Jan, Borska Lenka, Fiala Zdenek, Hamakova Kveta, Belobradek Michal, Ettler Karel
  International journal of dermatology 08/2011; 50(8):1033-5. · 1.18 Impact Factor
• Article: Goeckerman's therapy for psoriasis with special reference to serum pentraxin 3 level.

  Andrys Ctirad, Borska Lenka, Pohl David, Fiala Zdenek, Hamakova Kveta, Ettler Karel, Krejsek Jan
  [show abstract] [hide abstract]
  ABSTRACT: Goeckerman's therapy (GT) of psoriasis is based on daily application of pharmacy grade coal tar on affected skin with subsequent exposure to UV light. Pentraxin 3 (PTX3) is a newly identified acute phase reactant with non redundant functions in innate immunity. PTX3 has been shown to be a reliable prognostic marker in patients with various inflammatory disorders including rheumatoid arthritis, vasculitis, and psoriasis. The aim of this study was to evaluate the influence of Goeckerman's therapy of psoriasis on levels of two pentraxins: long pentraxin PTX3 and C reactive protein in 49 patients with chronic plaque psoriasis. CRP was assessed by immunonephelometry on IMMAGE 800 (Beckman, USA). PTX3 was detected using sandwich ELISA detection set (Alexis Biochemicals, Switzerland). The serum levels of both parameters (expressed as average +/- 1 SD) were significantly diminished after GT. The level of PTX3 dropped from 1.92 +/- 0.72 ng/ml before GT to 1.66 +/- 0.58 ng/ml after GT (P= 0.0396) and the level of CRP fell from 4.64 +/- 3.93 mg/l to 1.66 +/- 0.58 mg/l (P < 0.0001).Comparing to healthy controls, the serum levels of both parameters before GT were significantly higher than those found in healthy blood donors and remained significantly increased after GT. Increased serum concentrations of pentraxin 3 and CRP are alleviated by GT in patients with psoriasis.
  International journal of dermatology 11/2008; 47(10):1011-4. · 1.18 Impact Factor
• Article: Early Expression of FcγRI (CD64) on Monocytes of Cardiac Surgical Patients and Higher Density of Monocyte Anti-Inflammatory Scavenger CD163 Receptor in “On-Pump” Patients

  Kolackova Martina, Kudlova Manuela, Kunes Pavel, Lonsky Vladimir, Mandak Jiri, Andrys Ctirad, Jankovicova Karolina, Krejsek Jan
  [show abstract] [hide abstract]
  ABSTRACT: Objective. Activation of innate immunity cells is inseparably linked to cardiac surgical operation. The aim of this study was to assess the kinetics in the expression of receptor for Fc part of IgG, FcγRI (CD64), and scavenger receptor CD163 on peripheral blood cells of cardiac surgical patients and to examine the effect of cardiac bypass as a separable influence on the systemic acute inflammatory response. Methods. Forty patients, twenty in each group, were randomly assigned to CABG surgery performed either with “on-pump” or without “off-pump” cardiopulmonary bypass. Standardized quantitative flow cytometry method was used to determine the expression of surface markers. Results. The density of CD64 molecule on monocytes reached maximum on the 1st postoperative day (P<.001) whereas the peak for CD64 molecule expression on granulocytes was postponed to the 3rd postoperative day (P<.001). The expression of CD163 scavenger molecule on monocytes reached maximum on the 1st postoperative day (P<.001). The density of CD163 molecule on monocytes on the 1st postoperative day is significantly higher in “on-pump” patients in comparison with “off-pump” patients (P<.001). Conclusion. In cardiac surgical patients the expression of activation marker FcγR1 (CD64) on monocytes is increased earlier in comparison with granulocytes in both “on-pump” and “off-pump” patients. The expression of scavenger molecule CD163 on monocytes is significantly higher in “on-pump” patients.
  Mediators of Inflammation. 01/2008;